My ePortfolio Register   

IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.04.17
Views: 1922

Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA

Dr Bindra speaks with ecancer at AACR 2017 about the determination of PARP inhibitor sensitivity in brain tumour cells with IDH mutations

He describes how, from screening of a CRISPR-Cas9 model of mutant IDH cells, synthetic lethality with PARP inhibitory therapy was uncovered.

Dr Bindra highlights the current approval of PARP inhibitors in other indications, and outlines upcoming trials to further explore treatment options.

You can read more about the findings here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence